Dashboard
Manage Tickers

MRK Merck & Co., Inc.

NYSE merck.com


$ 87.08 $ 0.00 (0 %)    

Thursday, 23-Oct-2025 15:38:37 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 610.94 $ 0.00 (0 %)
DIA $ 467.43 $ 0.00 (0 %)
SPY $ 672.21 $ 0.00 (0 %)
TLT $ 91.45 $ 0.00 (0 %)
GLD $ 378.97 $ 0.00 (0 %)
$ 87.61
$ 87.54
$ 87.07 x 525
$ 87.08 x 177
$ 86.91 - $ 88.07
$ 71.87 - $ 103.53
10,926,343
na
218.83B
$ 0.27
$ 13.34
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-02-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-03-2024 03-31-2024 10-Q
7 02-26-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-05-2023 03-31-2023 10-Q
11 02-24-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-25-2022 12-31-2021 10-K
16 11-05-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 02-26-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 02-27-2018 12-31-2017 10-K
32 11-07-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 02-28-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 02-26-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

merck-to-present-new-research-from-its-cardio-pulmonary-portfolio-pipeline-at-american-heart-association-scientific-sessions-2025-in-new-orleans
Merck To Present New Research From Its Car...
10/23/2025 11:02:29

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the ...

merck-receives-us-fdas-priority-review-for-two-supplemental-biologics-license-applications-for-keytruda-keytruda-qlex-to-treat-muscle-invasive-bladder-cancer-fda-sets-april-7-2026-as-prescription-drug-user-fee-act-date
Merck Receives US FDA's Priority Review Fo...
10/23/2025 10:08:32

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administra...

merck--co-unusual-options-activity
Merck & Co Unusual Options Activity
10/22/2025 18:01:30

Core News & Articles
CNBC Halftime Report Final Trades: Thermo ...
10/22/2025 17:02:33

merck-presents-findings-from-systematic-literature-review-of-studies-on-epidemiology-and-amr-of-pneumococcal-serotypes-covered-by-capvaxive-in-us-adults-at-idweek-2025
Merck Presents Findings From Systematic Li...
10/21/2025 10:48:17

Findings presented at IDWeek 2025 underscore the importance of considering serotypes that disproportionately impact adults in t...

whats-going-on-with-summit-therapeutics-stock-on-monday
What's Going On With Summit Therapeutics S...
10/20/2025 14:05:00

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late...

merck-breaks-ground-on-3b-center-of-excellence-for-pharmaceutical-manufacturing-in-elkton-virginia
Merck Breaks Ground On $3B Center Of Excel...
10/20/2025 12:47:59

https://www.merck.com/news/merck-breaks-ground-on-3-billion-center-of-excellence-for-pharmaceutical-manufacturing-in-elkton-vir...

merck-says-keytruda-shows-sustained-long-term-survival-benefits-in-non-small-cell-lung-cancer-in-up-to-5-10-year-follow-up-studies
Merck Says KEYTRUDA Shows Sustained Long-T...
10/20/2025 12:47:04

Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall surviva...

merck-announces-start-of-construction-for-3b-400k-square-foot-pharmaceutical-manufacturing-facility-at-elkton-virginia-site
Merck Announces Start Of Construction For ...
10/20/2025 10:48:30

The expansion underscores Merck's commitment to invest more than $70 billion in U.S. research, development and capital proj...

Core News & Articles
Reported Sunday, Daiichi Sankyo And Merck'...
10/20/2025 07:20:41

An objective response rate of 50.5% was observed with raludotatug deruxtecan across all dose levels in these patients in the ph...

uk-finance-minister-seeks-more-pharma-investment-in-exchange-for-higher-drug-prices-report
UK Finance Minister Seeks More Pharma Inve...
10/16/2025 18:24:06

UK finance minister Rachel Reeves told reporters that the country needs to be an attractive place for pharma, including in term...

mercks-keytruda-plus-chemo-regimen-shows-overall-survival-benefit-in-recurrent-ovarian-cancer-patients
Merck's Keytruda Plus Chemo Regimen Shows ...
10/16/2025 14:33:43

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer...

merck-says-phase-3-keynote-b96-trial-engot-ov65-of-keytruda-combined-with-chemo-met-its-secondary-endpoint-of-overall-survival-for-platinum-resistant-recurrent-ovarian-cancer-in-all-comers
Merck Says Phase 3 KEYNOTE-B96 trial (ENGO...
10/16/2025 10:49:22

KEYNOTE-B96 is the first trial of an immune checkpoint inhibitor-based treatment regimen in platinum-resistant recurrent ovaria...

merck-kgaa-executives-signal-significant-ma-headroom-note-tariff-masked-margin-gains-and-markets-gradually-improving-in-life-science-and-electronics
Merck KGaA Executives Signal Significant M...
10/16/2025 07:48:36

-Reuters

mercks-new-hiv-treatment-works-as-well-as-top-drug-in-late-trials
Merck's New HIV Treatment Works As Well As...
10/15/2025 16:23:05

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase ...

merck-shares-additional-data-from-the-phase-3-studies-of-two-drug-regimen-of-doravirineislatravir-for-hiv-1-infection-that-was-virologically-suppressed-on-bictegraviremtricitabinetenofovir-alafenamidei-in-trial-mk-8591a-052-or-antiretroviral-therapy-in-trial-mk-8591a-051
Merck Shares Additional Data From The Phas...
10/15/2025 10:48:12

n trial MK-8591A-052, adults living with virally suppressed HIV-1 infection who switched to DOR/ISL from BIC/FTC/TAF showed min...

hedge-fund-shah-capital-urges-novavax-to-consider-sale-amid-vaccine-rollout-struggles-sees-5-billion-potential
Hedge Fund Shah Capital Urges Novavax To C...
10/14/2025 17:08:17

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...

tesla-to-300-here-are-10-top-analyst-forecasts-for-monday
Tesla To $300? Here Are 10 Top Analyst For...
10/13/2025 13:43:21

citigroup-reinstates-neutral-on-merck--co-raises-price-target-to-95
Citigroup Reinstates Neutral on Merck & Co...
10/13/2025 12:54:02

Citigroup analyst Geoff Meacham reinstates Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $84 to ...

uk-weighs-25-rise-in-drug-prices-as-pharma-giants-pause-investments
UK Weighs 25% Rise In Drug Prices As Pharm...
10/10/2025 16:25:30

UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION